Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Casi Pharmaceuticals Inc (NQ: CASI )

2.320 -0.180 (-7.20%)
Streaming Delayed Price Updated: 1:06 PM EDT, Apr 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Casi Pharmaceuticals Inc

< Previous 1 2 3 4 Next >
CASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
CASI stock results show that CASI Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Recap: CASI Pharmaceuticals Q4 Earnings
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
CASI Pharmaceuticals Blood Cancer Drug Shows Encouraging Clinical Efficacy In Chinese Patients
CASI Pharmaceuticals and BioInvent share promising results for BI-1206 in treating relapsed/refractory indolent Non-Hodgkin's Lymphoma patients in China. Preliminary data reveals clinical efficacy with... 
Via Benzinga
CASI Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
CASI Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
CASI Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Recap: CASI Pharmaceuticals Q2 Earnings
  CASI Pharmaceuticals (NASDAQ:CASI) reported its Q2 earnings results on Friday, August 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Week In Review: LianBio To Close Operations; Will Pay $528 Million To Shareholders
LianBio, a Princeton-Shanghai biotech, has decided to call it quits. LianBio plans to stop all of its operations by the end of 2024, and it will distribute a $4.80 dividend/share ($528 million) to its... 
Via Talk Markets
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for CASI Pharmaceuticals: Here's What You Need To Know
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Why VOXX International Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday morning and we're covering all of the latest news investors need to know about! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Week In Review: Mundipharma Considers $1 Billion Sale Of China Operations
Mundipharma is considering selling its China operations in a deal that could be worth $1 billion. Additionally, Oramed Pharma plans to form a $60 million JV with Hefei Tianhui Biotech to commercialize... 
Via Talk Markets
Week In Review: Novartis In $1 Billion Deal For DTx Pharma
Novartis signed a $1 billion agreement to acquire DTx Pharma, a preclinical San-Diego company developing siRNA therapies for neuroscience indications. Meanwhile, Zhuhai Biotheus formed a far-reaching... 
Via Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Week In Review: Sino Biopharma Subsidiary Enters $307 Million Agreement For Rights To NASH Candidate
Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharma, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from Inventiva in a $307 million deal. Meanwhile, CASI Pharma... 
Via Talk Markets
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers 
Via Benzinga
Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday
Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday. 
Via Benzinga
Week In Review: Beijing BoomRay Closes $43 Million A Round For Novel Radionuclide Drugs
Beijing BoomRay Pharma, a joint venture between WuXi AppTec and Peking University, completed a $43 million Series A funding to develop novel radionuclide drugs that integrate diagnosis and treatment. 
Via Talk Markets
$2.2 Million Bet On Terns Pharmaceuticals? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones closed higher by around 193 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or... 
Via Benzinga
CASI Pharmaceuticals Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q2, CASI Pharmaceuticals's (NASDAQ:CASI) reported sales totaled $8.57 million. Despite a 10.8% increase in earnings, the company posted a loss of $7.49... 
Via Benzinga
CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying
The Dow Jones tumbled by over 1,000 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
This Technology Stock Jumped 55% Following Q2 Results; Here Are 96 Biggest Movers From Yesterday
Gainers Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter hearing aids. 
Via Benzinga
Earnings Scheduled For August 12, 2022
Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million. 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.